Literature DB >> 24469825

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Courtney V Fletcher1, Kathryn Staskus, Stephen W Wietgrefe, Meghan Rothenberger, Cavan Reilly, Jeffrey G Chipman, Greg J Beilman, Alexander Khoruts, Ann Thorkelson, Thomas E Schmidt, Jodi Anderson, Katherine Perkey, Mario Stevenson, Alan S Perelson, Daniel C Douek, Ashley T Haase, Timothy W Schacker.   

Abstract

Antiretroviral therapy can reduce HIV-1 to undetectable levels in peripheral blood, but the effectiveness of treatment in suppressing replication in lymphoid tissue reservoirs has not been determined. Here we show in lymph node samples obtained before and during 6 mo of treatment that the tissue concentrations of five of the most frequently used antiretroviral drugs are much lower than in peripheral blood. These lower concentrations correlated with continued virus replication measured by the slower decay or increases in the follicular dendritic cell network pool of virions and with detection of viral RNA in productively infected cells. The evidence of persistent replication associated with apparently suboptimal drug concentrations argues for development and evaluation of novel therapeutic strategies that will fully suppress viral replication in lymphatic tissues. These strategies could avert the long-term clinical consequences of chronic immune activation driven directly or indirectly by low-level viral replication to thereby improve immune reconstitution.

Entities:  

Keywords:  FDC network; drug levels; pharmacokinetics

Mesh:

Substances:

Year:  2014        PMID: 24469825      PMCID: PMC3926074          DOI: 10.1073/pnas.1318249111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa.

Authors:  R Keith Reeves; Tristan I Evans; Jacqueline Gillis; Fay E Wong; Guobin Kang; Qingsheng Li; R Paul Johnson
Journal:  J Infect Dis       Date:  2012-06-18       Impact factor: 5.226

2.  Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients.

Authors:  Guillermo Isasti; Isabel Pérez; Tamara Moreno; Fernando Cabrera; Rosario Palacios; Jesús Santos
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-17       Impact factor: 2.205

Review 3.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 4.  Immune interventions in HIV infection.

Authors:  Guislaine Carcelain; Brigitte Autran
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

5.  Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States.

Authors:  Michael J Vinikoor; Sonia Napravnik; Michelle Floris-Moore; Susan Wilson; David Y Huang; Joseph J Eron
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-10       Impact factor: 2.205

6.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells.

Authors:  Hiroyu Hatano; Vivek Jain; Peter W Hunt; Tzong-Hae Lee; Elizabeth Sinclair; Tri D Do; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; Frederick Hecht; Michael P Busch; Steven G Deeks
Journal:  J Infect Dis       Date:  2012-10-22       Impact factor: 5.226

7.  Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.

Authors:  Kristine B Patterson; Heather A Prince; Trenton Stevens; Nicholas J Shaheen; Evan S Dellon; Ryan D Madanick; Steven Jennings; Myron S Cohen; Angela D M Kashuba
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

8.  High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.

Authors:  Andrea Calcagno; Jessica Cusato; Marco Simiele; Ilaria Motta; Sabrina Audagnotto; Margherita Bracchi; Antonio D'Avolio; Giovanni Di Perri; Stefano Bonora
Journal:  J Antimicrob Chemother       Date:  2013-08-23       Impact factor: 5.790

9.  Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.

Authors:  Hiroyu Hatano; Matthew C Strain; Rebecca Scherzer; Peter Bacchetti; Deborah Wentworth; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; James D Neaton; Russell P Tracy; Priscilla Y Hsue; Douglas D Richman; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-08-23       Impact factor: 5.226

10.  HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation.

Authors:  Jason V Baker; Kathleen Brummel-Ziedins; Jacqueline Neuhaus; Daniel Duprez; Nathan Cummins; David Dalmau; Jack DeHovitz; Clara Lehmann; Ann Sullivan; Ian Woolley; Lewis Kuller; James D Neaton; Russell P Tracy
Journal:  J Am Heart Assoc       Date:  2013-07-29       Impact factor: 5.501

View more
  332 in total

Review 1.  The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.

Authors:  Upal Roy; Jesse Rodríguez; Paul Barber; José das Neves; Bruno Sarmento; Madhavan Nair
Journal:  Nanomedicine (Lond)       Date:  2015-09-24       Impact factor: 5.307

2.  Analysis of Dominant HIV Quasispecies Suggests Independent Viral Evolution Within Spinal Granulomas Coinfected with Mycobacterium tuberculosis and HIV-1 Subtype C.

Authors:  Sivapragashini Danaviah; Tulio de Oliveira; Michelle Gordon; Shunmugam Govender; Paul Chelule; Sureshnee Pillay; Thajasvarie Naicker; Sharon Cassol; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2015-12-17       Impact factor: 2.205

3.  Alterations in P-Glycoprotein Expression and Function Between Macrophage Subsets.

Authors:  Theodore J Cory; Hui He; Lee C Winchester; Santosh Kumar; Courtney V Fletcher
Journal:  Pharm Res       Date:  2016-07-18       Impact factor: 4.200

4.  Systems Approach to targeted and long-acting HIV/AIDS therapy.

Authors:  Rodney J Y Ho; Jesse Yu; Bowen Li; John C Kraft; Jennifer P Freeling; Josefin Koehn; Jingwei Shao
Journal:  Drug Deliv Transl Res       Date:  2015-12       Impact factor: 4.617

5.  Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.

Authors:  G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

6.  Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.

Authors:  Erin Burgunder; John K Fallon; Nicole White; Amanda P Schauer; Craig Sykes; Leila Remling-Mulder; Martina Kovarova; Lourdes Adamson; Paul Luciw; J Victor Garcia; Ramesh Akkina; Philip C Smith; Angela D M Kashuba
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

7.  Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.

Authors:  David Palesch; Steven E Bosinger; Maud Mavigner; James M Billingsley; Cameron Mattingly; Diane G Carnathan; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Guido Silvestri
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 8.  HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy.

Authors:  Luis M Agosto; Pradeep D Uchil; Walther Mothes
Journal:  Trends Microbiol       Date:  2015-03-09       Impact factor: 17.079

9.  Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.

Authors:  Lisa A McConnachie; Loren M Kinman; Josefin Koehn; John C Kraft; Sarah Lane; Wonsok Lee; Ann C Collier; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2018-03-13       Impact factor: 3.534

10.  BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.

Authors:  Yanhui Cai; Mohamed Abdel-Mohsen; Costin Tomescu; Fengtian Xue; Guoxin Wu; Bonnie J Howell; Yong Ai; Jie Sun; Livio Azzoni; Carole Le Coz; Neil Romberg; Luis J Montaner
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.